Technical Analysis for OVID - Ovid Therapeutics Inc.
| ADX | Long Term | Intermediate Term | Short Term |
|---|---|---|---|
| Weak or Absent | Down | Down | Down |
| Date | Alert Name | Type | % Chg |
|---|---|---|---|
| 20 DMA Resistance | Bearish | 0.00% | |
| 50 DMA Resistance | Bearish | 0.00% | |
| Earnings Movers | Other | 0.00% | |
| Outside Day | Range Expansion | 0.00% | |
| Gapped Up | Strength | 0.00% | |
| 20 DMA Resistance | Bearish | 0.88% | |
| 50 DMA Resistance | Bearish | 0.88% | |
| NR7 | Range Contraction | 0.88% | |
| Narrow Range Bar | Range Contraction | 0.88% | |
| Fell Below 20 DMA | Bearish | -0.87% |
| Alert | Time |
|---|---|
| Up 5% | about 19 hours ago |
| Rose Above Previous Day's High | about 23 hours ago |
| 50 DMA Resistance | about 23 hours ago |
| 20 DMA Resistance | about 23 hours ago |
| 10 DMA Resistance | about 23 hours ago |
Get this analysis on your stocks daily!
- Earnings date: 11/01/2024
Ovid Therapeutics Inc. Description
Ovid Therapeutics Inc. (Ovid) is a biopharmaceutical company. The Company is engaged in developing medicines for patients and families living with rare neurological disorders. Its lead drug candidate is OV101. The Company’s second lead drug candidate is OV935. OV101 (gaboxadol) is a delta-selective GABAA receptor agonist. Ovid is developing OV101 for use in both Angelman syndrome and Fragile X syndrome to potentially restore tonic inhibition and relieve several of the symptoms of these disorders. Ovid has initiated the Phase II STARS trial of OV101 in adults with Angelman syndrome and a Phase I trial in adolescents with Angelman syndrome or Fragile X syndrome. Ovid is also developing OV935 in collaboration with Takeda Pharmaceutical Company Limited for the treatment of rare epileptic encephalopathies.
Classification
Sector: Healthcare
Industry: Biotechnology
Keywords: Biopharmaceutical Organ Systems Disorders Neurological Disorders Epilepsy Syndromes Urological Disorders Genodermatoses Sedatives Fragile X Syndrome Anticonvulsants Rare Neurological Disorders
| Indicator | Bull Case | Neutral / Hold | Bear Case |
|---|---|---|---|
| 50 DMA | |||
| 200 DMA | |||
| ADX Trend | |||
| Oversold / Overbought | |||
| Relative Strength |
| Indicator | Value |
|---|---|
| 52 Week High | 4.1 |
| 52 Week Low | 0.68 |
| Average Volume | 137,650 |
| 200-Day Moving Average | 2.18 |
| 50-Day Moving Average | 1.15 |
| 20-Day Moving Average | 1.16 |
| 10-Day Moving Average | 1.18 |
| Average True Range | 0.07 |
| RSI (14) | 47.09 |
| ADX | 11.5 |
| +DI | 13.37 |
| -DI | 14.52 |
| Chandelier Exit (Long, 3 ATRs) | 1.04 |
| Chandelier Exit (Short, 3 ATRs) | 1.23 |
| Upper Bollinger Bands | 1.23 |
| Lower Bollinger Band | 1.09 |
| Percent B (%b) | 0.37 |
| BandWidth | 12.53 |
| MACD Line | 0.01 |
| MACD Signal Line | 0.01 |
| MACD Histogram | -0.0059 |
| Pivot Point Level | Traditional / Classic | Fibonacci | Demark | Woodie | Camarilla |
|---|---|---|---|---|---|
| Resistance 4 (R4) | 1.28 | ||||
| Resistance 3 (R3) | 1.28 | 1.23 | 1.25 | ||
| Resistance 2 (R2) | 1.23 | 1.20 | 1.23 | 1.24 | |
| Resistance 1 (R1) | 1.19 | 1.18 | 1.17 | 1.19 | 1.24 |
| Pivot Point | 1.14 | 1.14 | 1.13 | 1.14 | 1.14 |
| Support 1 (S1) | 1.10 | 1.11 | 1.08 | 1.10 | 1.04 |
| Support 2 (S2) | 1.05 | 1.09 | 1.05 | 1.04 | |
| Support 3 (S3) | 1.01 | 1.05 | 1.03 | ||
| Support 4 (S4) | 1.01 |
